The average one-year price target for Geron (NASDAQGS:GERN) (LSE:0IV3) has been revised to $3.70 / share. This is a decrease ...

Geron (GERON) stock gains as the company turns profitable in Q3 2026 as blood cancer drug Rytelo drives revenue growth. Read ...

Geron unveiled its first-quarter numbers well before market open, showing that the oncology-focused biotech earned $39.6 million during the period. Nearly all of this was derived from sales of Rytelo, ...

For Geron Corporation GERN, 2024 was a transformational year as it saw the FDA approval and commercial launch of Rytelo (imetelstat) for the treatment of low- to intermediate-1 risk myelodysplastic ...

For that indication, Rytelo is dosed at 7.1 mg/kg administered as an intravenous infusion every four weeks. Thrombocytopenia ...

Geron achieved FDA approval for RYTELO in June 2024, targeting lower-risk myelodysplastic syndromes. Read what makes GERN ...

Geron (GERN) delivered earnings and revenue surprises of +100.00% and +0.37%, respectively, for the quarter ended September ...

Geron Corporation GERN shares plunged on Wednesday after the company halted its late-stage cancer program. Independent Panel ...

Geron stock is seeing a dramatic pullback following the company's fourth-quarter report. Geron's earnings in Q4 fell short of Wall Street's expectations, and management had worrying guidance for ...

Geron guides to USD 220.00-240.00 million for RYTELO in 2026. Geron stock costs EUR 1.07 on October 8, 2026 after EUR 1.08, ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an ...

Telomerase is a naturally occurring enzyme that lengthens the lifespan of frequently dividing cells. It's also abused by cancer cells that want to divide uncontrollably. Rytelo is the first approved ...